Glumetinib for lung cancer with MET changes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (18 or older, or the age of majority where you live) and sign consent
- Have confirmed non-small cell lung cancer (NSCLC), including people with a specific subtype (PSC)
- Have stage IIIb/IIIc not suitable for curative surgery or chemo-radiation, or stage IV cancer
- Your tumor must show a MET change (examples: MET exon 14 skipping, MET amplification, or MET over-expression) checked by local and/or central testing
- Have enough body strength to do daily activities (ECOG performance status 0–1) and adequate blood, liver, kidney levels
- If you’re in the Phase II part, you must have had 1–2 prior treatment “lines” for advanced cancer (or you can’t/choose not to have chemotherapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (Glumetinib) and chemotherapy (nab-docetaxel) against chemotherapy alone for people with advanced non-small cell lung cancer that has a high level of a protein called MET. It may offer a new option after standard immunotherapy and platinum chemo have stopped working.
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
This Phase 2 study tests ABN401 to see how well it works and how safe it is for people with advanced non-small cell lung cancer (NSCLC) that has certain c-MET (a protein) changes. It may help some tumors that have not responded well to prior treatment, especially certain EGFR-related cases.
This trial tests REGN5093, a study drug, in adults with advanced lung cancer that has a specific change called a MET alteration. If you have this MET change, the study aims to see how well the drug controls the cancer and how safe it is.
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
This study compares crizotinib to standard chemotherapy for people with advanced (spread) non-small cell lung cancer that has a specific change called MET exon 14 skipping. The goal is to see which treatment works better and how safely it controls the cancer.
Hear when a new C-Met Exon 14 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.